Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Omeros Corp (OMER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 941,913
  • Shares Outstanding, K 49,058
  • Annual Sales, $ 29,870 K
  • Annual Income, $ -126,760 K
  • 60-Month Beta 3.57
  • Price/Sales 31.16
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.00 +11.65%
on 05/10/19
20.16 -5.85%
on 05/06/19
+0.03 (+0.16%)
since 04/23/19
3-Month
13.80 +37.54%
on 02/26/19
20.16 -5.85%
on 05/06/19
+4.44 (+30.54%)
since 02/22/19
52-Week
10.30 +84.27%
on 12/24/18
27.00 -29.70%
on 09/25/18
-0.81 (-4.09%)
since 05/23/18

Most Recent Stories

More News
Omeros to Present at the UBS Global Healthcare Conference

Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next...

OMER : 18.98 (-1.15%)
Omeros Corp Shares Up 33.8% Since SmarTrend's Buy Recommendation (OMER)

SmarTrend identified an Uptrend for Omeros Corp (NASDAQ:OMER) on February 14th, 2019 at $14.22. In approximately 3 months, Omeros Corp has returned 33.76% as of today's recent price of $19.02.

OMER : 18.98 (-1.15%)
Top 5 Companies in the Pharmaceuticals Industry with the Best Relative Performance (OMER , PCRX , LCI , MDCO , ZGNX )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

LCI : 6.09 (+0.66%)
PCRX : 43.33 (-0.30%)
OMER : 18.98 (-1.15%)
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates

Omeros (OMER) delivered earnings and revenue surprises of -11.76% and -4.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OMER : 18.98 (-1.15%)
Omeros: 1Q Earnings Snapshot

SEATTLE (AP) _ Omeros Corporation (OMER) on Thursday reported a loss of $24.3 million in its first quarter.

OMER : 18.98 (-1.15%)
Omeros Corporation Reports First Quarter 2019 Financial Results

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market...

OMER : 18.98 (-1.15%)
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA(R) Presented at American Society of Cataract and Refractive Surgery Annual Meeting

Omeros Corporation(Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA(R) (phenylephrine and ketorolac intraocular...

OMER : 18.98 (-1.15%)
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after...

OMER : 18.98 (-1.15%)
38.2% Return Seen to Date on SmarTrend Omeros Corp Call (OMER)

SmarTrend identified an Uptrend for Omeros Corp (NASDAQ:OMER) on February 14th, 2019 at $14.22. In approximately 3 months, Omeros Corp has returned 38.19% as of today's recent price of $19.65.

OMER : 18.98 (-1.15%)
Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OMER : 18.98 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade OMER with:

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Key Turning Points

2nd Resistance Point 19.74
1st Resistance Point 19.47
Last Price 18.98
1st Support Level 18.72
2nd Support Level 18.24

See More

52-Week High 27.00
Fibonacci 61.8% 20.62
Last Price 18.98
Fibonacci 50% 18.65
Fibonacci 38.2% 16.68
52-Week Low 10.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar